By Blake Brittain

(Reuters) -A U.S. regulation enforcement company has decided that Apple (NASDAQ:) can use a redesign to bypass an import ban on newer Apple Watch fashions stemming from its patent infringement dispute with Masimo (NASDAQ:), the medical-monitoring expertise firm mentioned in a courtroom submitting on Monday.

The import ban, issued by the U.S. Worldwide Commerce Fee (ITC), applies to Apple’s present Sequence 9 and Extremely 2 watches and initially went into impact on Dec. 26. Apple satisfied the U.S. Courtroom of Appeals for the Federal Circuit to pause the ban the subsequent day, and has since resumed promoting the watches because it contests the import ruling.

Apple had mentioned {that a} proposed redesign would permit it to avoid findings that the watches infringe Masimo’s blood-oxygen studying pulse oximetry patents. Apple has not publicly described the redesign, which may contain an replace to the watches’ software program.

In keeping with Masimo’s submitting on Monday with the Federal Circuit, Apple instructed the U.S. Customs and Border Safety company that its redesigned watches “definitively don’t comprise pulse oximetry performance.” Apple’s filings with U.S. Customs and the company’s choice, issued Friday, haven’t been launched publicly.

Masimo could ask the ITC to overrule the customs company’s choice.

Representatives for Apple and Masimo didn’t instantly reply to requests for touch upon Monday.

Irvine, California-based Masimo has accused Apple of hiring away its staff and stealing its pulse oximetry expertise to make use of in Apple Watches after discussing a possible collaboration.

Apple has included a pulse oximeter function in smartwatches since its Sequence 6 Apple Watch in 2020.

Masimo sued Apple in California that 12 months, alleging that Apple stole commerce secrets and techniques associated to expertise for studying blood-oxygen ranges and infringed Masimo patents.

Apple countersued Masimo for patent infringement, calling Masimo’s authorized actions a “maneuver to clear a path” for a competing smartwatch. Masimo launched its W1 watch, which tracks blood-oxygen ranges and different well being indicators, in 2022.

Masimo requested the ITC in 2021 to bar Apple’s imports and gross sales of Apple Watches that allegedly infringed its patents. The ITC dominated for Masimo final 12 months and the ban went into impact in December. Apple briefly stopped gross sales of its newest Sequence 9 and Extremely 2 watches in america earlier than Christmas as a result of ITC choice, although they remained out there from different U.S. retailers together with Amazon (NASDAQ:), Finest Purchase (NYSE:), Costco (NASDAQ:) and Walmart (NYSE:). The tech large resumed promoting the watches Dec. 27 after the Federal Circuit mentioned it might pause the ban whereas it considers whether or not Apple’s enchantment ought to put the ITC’s choice on maintain.

The Federal Circuit remains to be contemplating whether or not to proceed the pause or reinstate the ban, which might apply to Sequence 9 and Extremely 2 Apple Watches with pulse oximetry expertise that don’t have the redesign.

Apple has argued that it’s prone to win the enchantment and that permitting the ban to remain in impact would trigger important hurt to the corporate, its suppliers and the general public.

Masimo has mentioned that sustaining the pause would harm its enterprise and popularity and “demoralize” its scientists and engineers. It additionally mentioned in its Monday submitting that the Customs choice undermines Apple’s argument that reinstating the ban would trigger the tech large irreparable hurt.